Browse by author
Lookup NU author(s): Professor Anne Dickinson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The Wilms tumor antigen 1 (WT1) antigen is over-expressed in human leukemias, making it an attractive target for immunotherapy. Most WT1-specific Cytotoxic T Lymphocytes (CTLs) described so far displayed low avidity, limiting its function. To improve the immunogenicity of CTL epitopes, we replaced the first-amino-acid of two known immunogenic WT1-peptides (126 and 187) with a tyrosine. This modification enhances 126Y analogue-binding ability, triggers significant number of IFN--producing T cells (P=0.0003), induces CTL that cross-react with the wild-type peptide, exerts a significant lytic activity against peptide-loaded-targets (P=0.0006) and HLA-A0201-matched-leukemic cells (P=0.0014). These data support peptide modification as a feasible approach for the development of a leukemia-vaccine.
Author(s): Al Qudaihi G, Lehe C, Negash M, Al-Alwan M, Ghebeh H, Mohamed SY, Saleh AJM, Al-Humaidan H, Tbakhi A, Dickinson A, Aljurf M, Dermime S
Publication type: Article
Publication status: Published
Journal: Leukemia & Lymphoma
Print publication date: 01/01/2009
ISSN (print): 1042-8194
ISSN (electronic): 1029-2403
Publisher: Taylor & Francis Ltd.
Altmetrics provided by Altmetric